Dr. Stefan Walzer

MAP - Market Access Podcast

Business EN ↓ 124 episodes

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market...

Be sure to visit the podcast's website and support the creator: marketaccess-pricingstrategy.de

Author

Dr. Stefan Walzer

Category

Business

Latest episode

Nov 15, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra? 01.09.2023

🎧 Listen to this podcast on your favourite podcast player:  https://lnkd.in/eGemZRTi    🇨🇭Switzerland has one of the highest healthcare spendings per person across the world! At the same time, one could also say that Switzerland has also one of the best healthcare systems...  💥 … but health care expert Dr. Peter Intra calls it still a developing country in terms of digitalisa...

How does an optimized communication strategy look like, Dr. Arne Näveke? 15.08.2023

Listen to this podcast on your favourite podcast player:  https://lnkd.in/eGemZRTi Companies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in...

How does the German evaluation committee work, Prof. Jürgen Wasem? 01.08.2023

Listen to this podcast on your favourite podcast player:  https://lnkd.in/eGemZRTi   New methods such as diagnostics need to be assessed and the included in the reimbursement catalogue in the outpatient setting in Germany. However, key question remains which requirements are needed for such an evaluation and who is responsible for it. In some instances the responsible body is a sub-commi...

How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? 15.07.2023

Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved? In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company st...

How do I get approved by the US FDA, Dr. Jamie Cross? 01.07.2023

In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would a company need to be involved and maybe even get advice? Additionally, the core question remains how could US FDA requirements be aligned with potential payer needs - are there any relationships? The #marketaccess veterans Dr. Stefan Walzer and Dr. J...

How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell? 15.06.2023

The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works.  The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore. With Medicare the government directly funds pharmaceuticals for 65+ years old population. With Medicaid the government fund low incom...

How does market access work in Japan, Heather Wellam? 01.06.2023

The market access experts Dr. Stefan Walzer and Heather Wellam are discussing the market access process in Japan, one of the largest health care markets in the world! In Japan not all products need to go through the full process, so an important question is, what the criteria are and what role does cost-effectiveness play in this market? What are the differences in the process between drugs a...

Would AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost) 15.05.2023

Since the original publication of this podcast, AI has received enormous public attention, and we have also seen an amazing increase in performance. This makes this discussion even more relevant - with this REPOST we want to give you the opportunity to hear it, in case you missed the first publication. Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in ar...

Is there a place for Real World Evidence in HTA, Dr. Karen Facey? 01.05.2023

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments.  One of these advocates is Dr. Ka...

How can people get equal access to pharmaceuticals, Dr. Nina Lathia? 15.04.2023

All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors,  wrote Dr. Utibe R. Essien in an  Jama article 2021 . But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and excl...

How to be successful in Canadian health care market access & pricing! 01.04.2023

Canadian health care reimbursement might be seen as complex and difficult. Well, not totally wrong… The reimbursement veteran Dr. Stefan Walzer discusses with the Canadian experts Louise Perrault and Nicole Tunstall the process for reimbursement and the specifics of Quebec. What are requirements and what might be important early steps to consider in order to plan for success. Additionally, the pri...

How can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard? 15.03.2023

EU Joint HTA will become reality for ATMPs and therapies in oncology by the end of 2024.   Anyhow, methods and processes are not yet communicated and established as of March 2023. Furthermore, there are no opportunities for early consultation to plan clinical trials and/or EU joint HTA dossiers. The core question still remains for which endpoints and comparators data would need to be submitte...

Is quality cancer care in Ukraine still possible, Yevgen Brovko? 01.03.2023

Cancer care is a challenge in all countries. Now imagine, how difficult it is to organize and manage cancer care in a war zone!   In this special MAP Podcast episode the Ukrainian market access expert Yevgen Brovko explains the situation and market access of cancer care before the Russian invasion and the current state in Ukraine. After a more broad overview, he also explains the Uk...

What are drivers for a positive approval by Health Canada, Fraidianie Sévignè? 15.02.2023

Regulatory processes might vary across the world, EMA and FDA are mostly known, but what are drivers by Health Canada? What to consider when expanding e.g. from the US into Canada with a medical device? Are there differences between US FDA and Canadian decisions for drugs? And if so, why? The reimbursement veteran Dr. Stefan Walzer and the regulatory expert for Canada, Fraidianie Sévignè, discuss...

EU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira Müller? 01.02.2023

In Europe, there are at least as many reimbursement assessment processes in place as European countries. Some of these are transparent and clearly defined like the German AMNOG process, others are even more complex and sometimes even unclear, dependent also on the product of interest. Anyhow, the European Commission has already decided that a European joint assessment will come into place in...

The US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?! 15.01.2023

It seems to be a given, that prices in the US are higher than in the rest of the world. But what might happen, if the US refuses to pay these higher amounts anymore? There are already changes either approved or heavily discussed like the pricing inflation act, the cap on out-of-pocket cost and the opportunity for Medicare negotiating prices starting in 2026. If the global price system changes...

What are the main obstacles in oncology market access, Ed Schoonveld? 01.01.2023

Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their...

Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach? 15.12.2022

In Europe there are many different options to get engaged with payers across different jurisdictions. Given the complexity, the benefit of these might be questioned by some. However, if the pathway is clear and the company knows how to approach payers and asks the right questions it provides valuable insights securing commercial success. Within the podcast the European, UK and German pathways are...

The AMNOG process - how does it work from a legal perspective, Alexander Meier? 01.12.2022

New, innovative drugs are assessed within the so-called AMNOG process in Germany. Given the legal nature of this process, lawyers also play an important role. At the end of the AMNOG process there is a legal contract – and also important, lawyers are experienced in negotiations by nature? If this is true and how lawyers can support market access teams is discussed between the AMNOG expert Dr. Stef...

What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer? 15.11.2022

In this special podcast episode Dr. Stefan Walzer jumps into the latest trends and researches around market access, reimbursement and pricing presented and discussed just beginning of November 2022 at ISPOR Europe. From 6th to 9th of November the leading European experts including Dr. Stefan Walzer have met and discussed in Vienna. Discussion topics ranged widely around market access and...

AMNOG Reform - will Germany remain the most attractive market for orphan drugs? 01.11.2022

Given the current reforms and adaptions in the German system, one can wonder if the German market might remain the most attractive to launch pharmaceutical products and especially orphan drugs. Are there still ways to get innovative products into the market and get paid well? What do we need to know in order to still gain from the strengths of the German market size and economic power? This might...

Why should Market Access Managers care about statistics, Alexander Schacht? 15.10.2022

Not everybody can be a statistician, but >The Effective Statistician< Alexander Schacht argues, that every Market Access Manager should work with statisticians and should learn how to communicate statistics effectively. Together with Dr. Stefan Walzer he is framing the needs and importance of statistics in the context of market access and reimbursement.  Don’t miss t...

How might digitization change health care in Germany by 2035, Julian Molitor? 01.10.2022

Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Anyway, some core questions remain such as reimbursement for high risk medical devices, e.g. artificial intelligence (AI)...

Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering? 15.09.2022

Within the opportunity of contracting in the German health care market, prices, reimbursement and integrated care paths could be agreed on. However, for some medical devices, especially in the outpatient setting, selective contracts could be the most attractive pathway to enter into reimbursement agreements. Dr. But which health insurance companies should contacted and how? What makes a conta...

Would AI substitute or (only) support market access managers, Dr. Andree Bates? 01.09.2022

Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, w...

Listen to the MAP - Market Access Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.